drugset / Trial / NCT00146172
Study Evaluating HKI-272 in Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability as well as find the maximum tolerated dose (MTD) for HKI-272. In addition, this study will examine the effects of the study drug on your tumor, and how your body uses and eliminates HKI-272.
Timeline
- Start
- 2003-11
- Primary completion
- 2007-01
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | 40 mg | Oral |
| Subject | Neratinib | Small molecule | 80 mg | Oral |
| Subject | Neratinib | Small molecule | 120 mg | Oral |
| Subject | Neratinib | Small molecule | 180 mg | Oral |
| Subject | Neratinib | Small molecule | 240 mg | Oral |
| Subject | Neratinib | Small molecule | 320 mg | Oral |
| Subject | Neratinib | Small molecule | 400 mg | Oral |